Sunday, January 24, 2010

Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products

Over 45% of all new indication approvals granted by the FDA since 1998 belong to drugs that fall in the Genito-urinary system and Nervous system.

Optimizing Lifecycle Management, a best selling report explains the basics of drug lifecycle and investigates three goals in optimizing product potential- expanding the drug’s patent protected lifespan, accessing broader patient populations and launching line-extensions via FDCs.

The need to derive the maximum commercial mileage from all components of a drug company’s portfolio is clearly evident in an era of falling returns on investment and higher capital costs. This best selling report investigates three goals in optimizing product potential- expanding the drug’s patent protected lifespan, accessing broader patient populations and launching line-extensions via fixed dose combinations.

The key success factors in each of these pursuits have been clearly identified, emerging trends have been presented and the underlying concepts have been explained to provide a clear understanding of current industry dynamics. Case studies on popular products have been used to illustrate these concepts in the real world. An in-depth analysis of drug approval data provides context for the issues discussed. This information is juxtaposed with historic sales data to explore the correlation between the strategies employed and revenue potential.

Gain an understanding of legal provision for patent protection and data exclusivity and understand their role in the context of product lifecycle management with this report from Business Insights, market leaders in strategic business information. Click here for more information on this title.


Share this article with your social network, just click below to share now!


No comments :

Post a Comment